Biopharma Stocks Outperforming in $471 Billion Market (STAB, GILD, EXEL, MRK, JNJ)

Biopharmaceutical stocks are soaring this year. As a sector, the biopharma industry has grown 38% per year over the past three years. Sector stock revenues have grown cumulatively 10% annually and are seen repeating that performance for the next five years.

Biopharma will be a $471.02 billion market by 2027, according to stocknews.com, growing at a CAGR of 9.1+%. 

Biopharma companies are researching vaccines and treatments for COVID-19, COVID-19 long-haul, pediatric Crohn’s disease plus cancers and Alzheimer’s disease.

WHY IT MATTERS TO INVESTORS

This sector of stocks is not only outperforming the market, it also clinically tests the performance of commercially-potential candidate drugs. The goal is to address diseases that range from the pandemic of COVID-19 to cancers and addictive smoking impacting the lungs.

Here are the leading biopharmaceutical stocks you can buy. Starting with STAB a stock making progress on a pilot study protocol with the FDA.

BIOPHARMA STOCKS YOU CAN BUY

— Statera Biopharma, Inc. (NASDAQ: STAB) submits pilot study protocol of its clinical study of long haul COVID-19. The protocol is for its STAT-205 drug candidate and treatment of long haul post-acute SARS-CoV-2.

“Submitting this study protocol to the FDA is a critical milestone in the development of our COVID-19 program. As the world continues to struggle with the COVID-19 pandemic, post-acute COVID syndrome remains a widespread often debilitating condition that is not well understood,” says Michael K. Handley, president and CEO of the biopharmaceutical company. “With STAT-205 Statera looks to potentially offer a promising treatment approach to those patients facing the long-lasting burden of the illness.”

“We have taken numerous steps to further the development of our clinical-stage pipeline that has us well-positioned to achieve numerous milestones in 2022,” says Handley.

STAB RESEARCHING TREATMENT OF LONG HAUL COVID-19

Investors should put STAB stock on their Watch Lists as biopharmaceutical companies performing clinical stage research are rising in valuation.

STAT-205 is currently being evaluated in Phase 1 clinical trial in adult patients with mild COVID-19 who are at high risk of disease progression. It is halfway through its patient enrollment. Enrollment is expected to be completed in Q3 with top-line results available in Q4.

STAB is a clinical-stage biopharmaceutical company. It specializes in researching immunotherapies targeting autoimmune neutropenia/anemia emerging viruses. The goal is to develop a proprietary platform designed to rebalance the body’s immune system and remote homeostasis. The Company has clinical programs for Crohn’s disease and deadly pancreatic cancer. 

OTHER BIOPHARMACEUTICAL SECTOR STOCKS TO BUY INCLUDE

— Gilead Sciences, Inc. (NASDAQ: GILD) is an American biopharmaceutical stock that specializes in the R&D of anti-viral drugs addressing HIV, hepatitis, and influenza. GILD has developed several commercialized drugs such as Biktarvy and Genvoya for HIV and Veklury® for COVID-19. For its fiscal year ended December 31, its volume rose 10.6% to $27.3 billion.

Last month it declared a 2.8% higher quarterly dividend indicative of its strong balance sheet and ability to pay back shareholders. Earlier this yea with r it received expedited approval from the FDA of its drug Veklury®. It is formulated for the treatment of non-hospitalized patients at risk of progression to severe COVID-19.  

— Alexis, Inc. (NASDAQ: EXEL)is a biopharmaceutical company focused on R&D for cancer cures. It has beaten the consensus estimates of analysts. Volume spiked 67% to $ 451.1 million for the Q4 current completed quarter vs $270 million for the comparable quarter the prior year. 

This is a company focused on oncology and developing treatments for cancers. It has research collaborations and license with several notable companies. It is currently working on R&D and commercialization of a novel anti-cancer compound. This in-house license agreement strengthens its pipeline.

— Merck (NYSE: MRK) has grown share EPS by 28% annually, by compound, over the past three years. Over the past 12 months, MRK’s EBIT margins improved by 4% to 37%. This is a US $192 billion company.

This is a successful drug maker. Driving sales have been its products Keytruda, Lynparza and Bridion. They are all formulated to treat lung cancers and other cancers. In MRK’s pipeline are a promising oral antiviral pill.

— Johnson & Johnson (NYSE: JNJ) may be a special buy opportunity after its recent $100 million baby power settlement. Insider investors know that J&J will use a subsidiary, such as LTL Management, as part of its legal strategy to take the financial hit, according to Forbes. That way its core business would not be impacted.

J&J has an extensive late-stage drug pipeline. It has an aggressive pipeline and line extensions and sees the biopharmaceutical industry receiving in 2022 from its performance in 2021. J&J maintains a strong cash position enabling it to grow its biopharma business.  

Keep STAB stock on your Watch List as biopharmaceutical companies are increasing in value as clinical research studies intensify. Link to more news at https://www.staterabiopharma.com/

Disclaimers: Capital Gains Report ‘CGR’ is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by CGR is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall CGR. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by CGR., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. CGR. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, CGR., its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. CGR has been compensated one thousand five hundred dollars via wire transfer per release by Crossroads to produce and syndicate content for STAB. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

Media Contact
Company Name: Capital Gains Report
Contact Person: Mark McKelvie
Email: Send Email
City: FORT MYERS
State: FLORIDA
Country: United States
Website: http://capitalgainsreport.com/